High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. While limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined. To evaluate the efficacy of IFX, 7.5 to 10 mg/kg, with a maintenance frequency every four weeks (q4w). Prospective analysis of 42 patients initiating 'IFX 7.5' mg/kg q4w and 16 patients receiving dose-escalation to 'IFX 10' mg/kg q4w between 03/01/2018 and 02/28/2019. The primary outcome measure (clinical response) was the proportion of patients with HS-PGA of clear, minimal, or mild (0-2) with at least a 2-grade improvement from baseline scores. The proportion of patients achieving a clinical response after initiating IFX 7.5 was 20/42 (47.6%) at week 4, and 17/24 (70.8%) at week 12. For patients receiving dose-escalation to IFX 10 due to incomplete initial response, 6/16 (37.5%) achieved clinical response at week 4, and 6/12 (50%) at week 12. Initiation of IFX 7.5 q4w, with possible dose-escalation to IFX 10, if needed, provides optimal mitigation of HS-related disease activity.